GlassScriptPhysician profile
Jonathan William Martin
NPI 1902172083
$1,450.09
in general payments reported to CMS, 2019-2025
9 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $235 · 2021: $150 · 2022: $19.20 · 2023: $199 · 2024: $27.29 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $735.76 | 2019-2025 | |
| Viiv Healthcare Company | $329.78 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $122.97 | 2019-2023 | |
| Janssen Biotech, INC. | $105.93 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $43.49 | 2019-2020 | |
| Dynavax Technologies Corporation | $35.37 | 2019-2020 | |
| Astellas Pharma US INC | $33.89 | 2019 | |
| Melinta Therapeutics, LLC | $23.89 | 2019 | |
| Napo Pharmaceuticals INC | $19.01 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.